Nancy Kernan is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in New York, New York. Kernan has been practicing medicine for over 45 years and is rated as an Elite expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. She is also highly rated in 10 other conditions, according to our data. Her top areas of expertise are Hepatic Venoocclusive Disease with Immunodeficiency, Graft Versus Host Disease (GvHD), Leukemia, Adult T-Cell Leukemia, and Bone Marrow Transplant. She is licensed to treat patients in New York. Kernan is currently accepting new patients.
Robert Soiffer is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Soiffer has been practicing medicine for over 40 years and is rated as an Elite expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. He is also highly rated in 27 other conditions, according to our data. His top areas of expertise are Graft Versus Host Disease (GvHD), Hepatic Venoocclusive Disease with Immunodeficiency, Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), and Bone Marrow Transplant. He is licensed to treat patients in Massachusetts. Soiffer is currently accepting new patients.
Stephan Grupp is a Pediatric Hematologist Oncology specialist and a Pediatrics expert in Philadelphia, Pennsylvania. Grupp has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Hepatic Venoocclusive Disease with Immunodeficiency. He is also highly rated in 12 other conditions, according to our data. His top areas of expertise are Hepatic Venoocclusive Disease with Immunodeficiency, Acute Lymphoblastic Leukemia (ALL), Adult T-Cell Leukemia, Leukemia, and Bone Marrow Transplant. He is licensed to treat patients in Pennsylvania. Grupp is currently accepting new patients.
Summary: The long-term goal of our research is to accurately identify SOS patients who would benefit from defibrotide treatment using US SWE. The overall objective of this study is to validate SWE as an early diagnostic marker for SOS. Our central hypothesis is that SWE changes will precede clinical and conventional US diagnostic criteria for SOS. Our hypothesis has been formulated on the basis of our own ...
Summary: To evaluate efficacy and safety of AT-III treatment in patients with hepatic veno-occlusive diseases following hematopoietic stem cell transplantation.